AstraZeneca Pharma India gets DCGI nod to market cancer drug in India

New Delhi: Drug firm AstraZeneca Pharma India today said it has received permission from the Drug Controller General of India (DCGI) to import and market olaparib tablets used for the treatment of ovarian and breast cancer. The permission from the DCGI is for olaparib (Lynparza) tablets in the strengths of 100 mg and 150 mg, AstraZeneca Pharma India said in a BSE filing.

The tablets are a patented product of the AstraZeneca group, it added.

“The import and market permission for olaparib is a significant milestone for women in India living with platinum-sensitive relapsed ovarian cancer and BRCA-mutated HER-2 negative metastatic breast cancer, which has historically been difficulty-to-treat diseases,” AstraZeneca Pharma India MD Gagan Singh said.

Shares of AstraZeneca Pharma India today closed at Rs 1,710.30 per scrip on BSE, up 1.59 per cent from their previous close.

  • Related Posts

    KGMU prof suspended for forcing patients to buy meds from pvt store

    Lucknow: Faculty member in the ophthalmology department of KGMU, Prof Sanjiv Gupta, was suspended on charges of prescribing medicines and lenses for cataract surgery that were available at a private…

    CDSCO receives 1,387 adverse drug reaction reports in nine months of 2025

    New Delhi: The pharmacovigilance division of the Central drug regulator has received a total of 1,387 adverse reports, with the highest regarding fixed dose combinations (FDCs), and a total of…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    KGMU prof suspended for forcing patients to buy meds from pvt store

    KGMU prof suspended for forcing patients to buy meds from pvt store

    World Record in Robotic Tele-Surgery takes Intercontinental Leap of 20,000 Km

    World Record in Robotic Tele-Surgery takes Intercontinental Leap of 20,000 Km

    CDSCO receives 1,387 adverse drug reaction reports in nine months of 2025

    CDSCO receives 1,387 adverse drug reaction reports in nine months of 2025

    NGT issues notice to Himachal pharma unit over pollution, water diversion allegations

    NGT issues notice to Himachal pharma unit over pollution, water diversion allegations

    Zydus Semaglutide approval: Delhi HC directs CDSCO to decide on patient safety concerns

    Zydus Semaglutide approval: Delhi HC directs CDSCO to decide on patient safety concerns

    DGFT Fixes Six New Standard Input Output Norms (SIONs) for Pharmaceutical and Chemical Exports

    DGFT Fixes Six New Standard Input Output Norms (SIONs) for Pharmaceutical and Chemical Exports